CalibratevsNoom Med

Calibrate is not a drug; it is a "Metabolic Reset" coaching program built around a GLP-1 prescription. A clinician reviews your intake and lab work and, when medically appropriate, prescribes a GLP-1 receptor agonist (such as semaglutide/Wegovy or tirzepatide/Zepbound). These medications mimic gut hormones that slow stomach emptying, reduce appetite, and quiet food cravings, so you tend to eat less. On top of the medication, Calibrate layers an app-based curriculum and a coach you meet roughly every two weeks via video, targeting four pillars: food, sleep, exercise, and emotional health. The intent is that the drug curbs hunger while the coaching builds habits meant to help sustain weight loss; durable results after stopping the medication are not guaranteed.

Noom Med combines two things. First, a licensed clinician reviews an online health assessment and, if appropriate, prescribes a weight-management medication: a compounded or brand-name GLP-1 receptor agonist (semaglutide, the active ingredient in Ozempic/Wegovy), a dual GLP-1/GIP receptor agonist (tirzepatide, the active ingredient in Mounjaro/Zepbound), or an oral option such as metformin. GLP-1 medications mimic a gut hormone that curbs appetite, slows stomach emptying so you feel full longer, and helps regulate blood sugar; tirzepatide adds a second incretin pathway (GIP). Metformin works differently, mainly by reducing the liver's glucose output and improving insulin sensitivity. Second, the Noom app delivers daily cognitive-behavioral-therapy-style lessons on food psychology, habit formation, and emotional eating, plus 1:1 and group coaching, to support the lifestyle changes that help weight-loss results last.

Calibrate's own outcomes reports describe average weight loss of about 16% of body weight at one year (N=37,031), rising to roughly 18% at year two (N=11,132), 20% at year three (N=2,461), and 21% at year four (N=620), with metabolic gains such as about 80% of members who started with diabetes or prediabetes reaching normal HbA1c within a year. Important caveat: these are company-reported, retrospective figures from Calibrate's internal database (its 2026 Results Report and conference presentations), not results from an independent peer-reviewed randomized controlled trial, and the shrinking sample sizes in later years reflect members who stayed enrolled (survivorship bias). The robust peer-reviewed evidence sits with the underlying medications: in the NEJM-published STEP 1 trial, semaglutide 2.4 mg produced about 14.9% average weight loss versus 2.4% for placebo over 68 weeks, and in the head-to-head SURMOUNT-5 trial tirzepatide produced about 20.2% versus semaglutide's 13.7% at 72 weeks. Calibrate's results are broadly consistent with those drug trials plus coaching, but should be read as program marketing data, not independent proof.

The medications Noom prescribes carry strong trial evidence, though that evidence comes from the full-dose, FDA-approved products rather than compounded or microdose versions. In the STEP 1 trial (New England Journal of Medicine, 2021), once-weekly semaglutide 2.4 mg plus lifestyle intervention produced a mean 14.9% body-weight loss at 68 weeks versus 2.4% with placebo, with about 69% of treated participants losing at least 10% of their body weight. In SURMOUNT-1 (New England Journal of Medicine, 2022), tirzepatide produced average weight loss of roughly 16.0% to 22.5% depending on dose. Important caveats: Noom's lower-priced plans use compounded GLP-1s, and its Microdose plan deliberately uses doses below the standard maintenance levels studied in these trials, so individual results may be smaller than the headline trial figures. Noom's own 2026 engagement report (observational, 14,203 GLP-1 program members) found that the most-engaged app users lost about 8.3 lbs more by week 40 and stayed on their medication roughly twice as long (about 2.2x) over the first year compared with the least engaged, but the company itself notes this shows correlation, not proof that the app causes the difference. Individual results vary.

Side effects come from the GLP-1 medication, not the coaching. The most common are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and indigestion, usually worst when starting or increasing the dose and often easing over time. Less common but serious risks include pancreatitis, gallbladder problems (including gallstones), kidney injury from dehydration due to vomiting or diarrhea, and rare allergic reactions; severe or persistent abdominal pain warrants stopping the drug and seeking medical care. GLP-1s carry an FDA boxed warning for thyroid C-cell tumors seen in rodents (human relevance is unknown) and are contraindicated with a personal or family history of medullary thyroid cancer or MEN 2. Discuss any gallbladder, pancreas, kidney, eye, or mental-health history with the prescriber before starting.

The most common GLP-1 and tirzepatide side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal pain, and reflux, usually worst when starting or increasing the dose and often easing over time. Lower-dose (microdose) regimens are marketed partly to blunt these effects, though that benefit is not established in large trials. Serious but less common risks include pancreatitis, gallbladder problems such as gallstones, kidney injury from dehydration, and, in rodent studies, thyroid C-cell tumors, which is why these drugs carry a boxed warning; a causal link to thyroid cancer in humans has not been established. A specific concern with compounded semaglutide: the FDA has warned of dosing errors in which patients received 5 to 20 times the intended dose from multi-dose vials, with adverse events including severe vomiting, fainting, dehydration, and some hospitalizations. Follow dosing instructions exactly, report severe or persistent abdominal pain promptly, and seek medical care for any serious reaction.

As of 2026, Calibrate's membership runs about $199/month with a 3-month minimum (roughly $597 to start), covering 1:1 video coaching, the curriculum, a connected smart scale, app access, and insurance navigation. This fee is not reimbursed by insurance but is HSA/FSA eligible. Medication and lab costs are separate and billed through your insurance; members with commercial coverage often report GLP-1 copays around $25/month or less after meeting a deductible, but if your plan excludes GLP-1s for weight loss, out-of-pocket drug costs can run hundreds to over $1,000 per month. Calibrate offers a guarantee: members who do not lose at least 10% of body weight over 12 consecutive months may be eligible for 50% of their membership fees back. Budget for the membership plus uncertain medication costs, and confirm GLP-1 coverage before committing.

As of September 2026, Noom Med's pricing page lists GLP-1Rx Plus at $149 for the first four weeks, then $299/month billed quarterly, and a Proactive Health microdose plan at $149 every four weeks; both include medication. Insurance rarely covers compounded programs, so expect an ongoing out-of-pocket cost. Noom changes its plans often — confirm the current lineup before enrolling.

Calibrate is designed for U.S. adults with obesity (BMI 30+) or who are overweight (BMI 27+) with a weight-related condition such as prediabetes, high blood pressure, or sleep apnea, and who want medication plus coaching rather than medication alone. It is not appropriate during pregnancy or breastfeeding, or for people with type 1 diabetes. GLP-1 medications carry an FDA boxed warning and are contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). People with a history of pancreatitis, gallbladder disease, severe gastrointestinal disease, diabetic retinopathy, or active eating disorders should be cautious and disclose this to the clinician, who makes the final prescribing decision. Calibrate does not enroll people seeking weight loss without a qualifying BMI/health profile.

Noom Med is aimed at US adults who qualify for prescription weight management, typically a BMI of 30 or higher (obesity) or 27 or higher (overweight) with a weight-related condition such as type 2 diabetes, high blood pressure, or sleep apnea; final eligibility is determined by the clinician after intake, and clinical guidelines, not a website, govern who should be treated. It is not appropriate for people who are pregnant or breastfeeding, those with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, those with a history of pancreatitis, or anyone with known hypersensitivity to the prescribed drug. Anyone with gallbladder disease, diabetic retinopathy, severe kidney or liver disease, or significant gastrointestinal disorders should disclose this to the clinician. People who specifically want an FDA-approved drug should choose the brand-name telehealth tier rather than the compounded plans. The compounded Microdose plan is also unavailable in some states (such as Alabama, Arkansas, Iowa, Louisiana, and Mississippi) due to state rules on compounded medications.